Cortical Resections in Drug Resistant Epilepsy
NCT04553354 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 35
Last updated 2020-09-17
Summary
The aim of the study is to evaluate safety and efficacy of epilepsy surgery in the form of cortical resections in patients with refractory epilepsy and to review outcomes of resection procedures in focal epilepsy.
Conditions
- Epilepsy Surgery
- Drug Resistant Epilepsy
Interventions
- PROCEDURE
-
cortical resections
is the removal of the epileptic focus either temporal or extra temporal area
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-09-10
- Primary Completion
- 2022-09-10
- Completion
- 2022-11-10
More Related Trials
-
Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
NCT04714996 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
NCT02495844 ·Status: COMPLETED ·Phase: PHASE2
-
Cognitive Impairment in Drug-resistant and Drug-responsive Focal Cryptogenic Epilepsy
NCT06210022 ·Status: RECRUITING
-
Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion
NCT04529954 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Minimally Invasive Surgical Epilepsy Trial for Temporal Lobe Epilepsy
NCT05019404 ·Status: UNKNOWN ·Phase: NA
-
Study of Specimens Obtained During Epilepsy Surgery
NCT00025714 ·Status: COMPLETED
-
Precision Medicine in the Treatment of Epilepsy
NCT05450822 ·Status: RECRUITING
-
Early Surgical Intervention to Treat Epilepsy
NCT00040326 ·Status: COMPLETED ·Phase: PHASE3
-
Preoperative Speech Rehabilitation in Drug-Resistant Temporal Epilepsy: A Case Study
NCT05325047 ·Status: COMPLETED ·Phase: NA
-
Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery
NCT00887861 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
NCT05159908 ·Status: COMPLETED ·Phase: PHASE2
-
Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies
NCT02890641 ·Status: RECRUITING
-
An Observational Study of Epilepsy: Biology and Outcomes Using Real-world Data
NCT05632978 ·Status: RECRUITING
-
Multimodal Study of the Human Brain Epilepsy Tissue
NCT06022055 ·Status: RECRUITING ·Phase: NA
-
A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures
NCT01777139 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures
NCT00422110 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
MiCrobiota-gut-brain Axis in Resistant Epilepsy
NCT07010445 ·Status: RECRUITING ·Phase: NA
-
Human Epilepsy Project 2: Resistant Focal Seizures Study
NCT03531008 ·Status: COMPLETED
-
Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy
NCT00522522 ·Status: COMPLETED
-
Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
NCT05493293 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy
NCT03373383 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of GWP42006 in People With Focal Seizures - Part B
NCT02365610 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy
NCT07238868 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization
NCT04153175 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy
NCT02660255 ·Status: APPROVED_FOR_MARKETING